Skip to Content

Generic Zmax Availability

Zmax is a brand name of azithromycin, approved by the FDA in the following formulation(s):

ZMAX (azithromycin - for suspension, extended release;oral)

  • Manufacturer: PF PRISM CV
    Approval date: June 10, 2005
    Strength(s): EQ 2GM BASE/BOT [RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zmax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Azithromycin dihydrate
    Patent 6,268,489
    Issued: July 31, 2001
    Inventor(s): Allen; Douglas J. M. & Nepveux; Kevin M.
    Assignee(s): Pfizer Inc.

    Non-hygroscopic, azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin) dihydrate and a process therefor.

    Patent expiration dates:

    • July 31, 2018
      Drug substance
  • Azithromycin dosage forms with reduced side effects
    Patent 6,984,403
    Issued: January 10, 2006
    Inventor(s): Hagen; Timothy A. & Lo; Julian B. & Thombre; Avinash G. & Herbig; Scott M. & Appel; Leah Elizabeth & Crew; Marshall David & Friesen; Dwayne Thomas & Lyon; David Keith & McCray; Scott Baldwin & West; James Blair
    Assignee(s): Pfizer Inc.

    The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

    Patent expiration dates:

    • February 14, 2024
      Drug product
  • Multiparticulate crystalline drug compositions having controlled release profiles
    Patent 7,887,844
    Issued: February 15, 2011
    Inventor(s): Appel; Leah E. & Ray; Roderick J. & Lyon; David K. & West; James B. & McCray; Scott B. & Crew; Marshall D. & Friesen; Dwayne T. & Herbig; Scott M. & Lo; Julian B.
    Assignee(s): Pfizer Inc.

    A multiparticulate for controlled release of a drug comprises crystalline drug, a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a poloxamer, wherein at least 70 wt % of the drug in the multiparticulate is crystalline.

    Patent expiration dates:

    • February 14, 2024
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.